Cronos Group Inc.
CRON NasdaqΒ· Medicinal Chemicals & Botanical Products
Last close Β· Oct 27, 2026
$3.38
KIRA Β· Stoqlyβs AI analyst, in plain words
- Cronos Group Inc. had $147M of revenue in fiscal 2025, up 24.6% on the year before. Over five years, revenue changed +25.7% a year on average.
- Its operating margin was β11.9%, up 53.2Β pts: of every 100 in sales, about β12 is left after running the business.
- Cronos Group Inc. lost $9.4M in fiscal 2025.
- Free cash flow was $0.1M in fiscal 2025, 0.1% of revenue.
- Cronos Group Inc. returned $9.7M to shareholders in fiscal 2025, 6,538% of free cash flow. The diluted share count fell 0.5%.
Market cap
$1.3B
P/E
17.8x
Revenue
$147M
Net income
β$9.4M
Free cash flow
$0.1M
Operating margin
β11.9%
Cronos Group Inc. in 30 seconds Β· fiscal 2025
Are sales growing?
+24.6%
Yes. Sales grew 24.6% last year.
Does it make a profit?
β6.4%
No. It lost money last year.
Does profit turn into cash?
0.1%
Partly. 0.1% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
17.8x
One share costs 17.8 times its yearly profit per share.
What Cronos Group Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 26, 2026
- Legal name
- Cronos Group Inc.
- CIK
- 0001656472
Cronos Group Inc. Β· CRON
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $64.6M | $86.7M | $87.2M | $118M | $147M |
| Revenue growth | 38.2% | 34.4% | 0.6% | 34.8% | 24.6% |
| Gross margin | β27.3% | 17.8% | 13.7% | 21.4% | 42.8% |
| Operating margin | β452.2% | β128.4% | β97.2% | β65.1% | β11.9% |
| Net income | β$396M | β$169M | β$74.0M | $41.1M | β$9.4M |
| Net margin | β613.5% | β194.5% | β84.8% | 34.9% | β6.4% |
| Diluted EPS | β$1.07 | β$0.45 | β$0.19 | $0.11 | β$0.02 |
| Cash | |||||
| Cash from operations | β$154M | β$88.9M | β$42.8M | $18.8M | $25.9M |
| Capital expenditure | $11.1M | $3.5M | $2.5M | $12.4M | $25.7M |
| Free cash flow | β$165M | β$92.4M | β$45.3M | $6.4M | $0.1M |
| FCF margin | β255.2% | β106.5% | β52.0% | 5.5% | 0.1% |
| Share buybacks | β | β | $0.0M | $0.0M | $9.7M |
| Share count change | 5.4% | 1.8% | 1.1% | 1.2% | β0.5% |
| Debt and strength | |||||
| Cash and short-term investments | $1.0B | $878M | $862M | $859M | $832M |
| Shareholders' equity | $1.3B | $1.1B | $1.1B | $1.1B | $1.1B |
| Current ratio | 19.9x | 14.1x | 22.5x | 18.8x | 19.6x |
| Interest coverage | β10,813.7x | β8,571.4x | β | β | β |
| Returns and quality | |||||
| Return on equity | β26.0% | β13.6% | β6.6% | 3.8% | β0.9% |
| Return on tangible equity | β30.1% | β15.1% | β6.9% | 4.2% | β0.9% |
| Piotroski F-score | 4 | 4 | 4 | 5 | 6 |
| Altman Z'' | 27.1 | 22.2 | 32.0 | 26.0 | 27.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cronos Group Inc. Β· CRON
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.38 a share, the company is worth $1.3B: 17.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001656472). Data updated October 24, 2026. For information only β not investment advice. Check the original filings before relying on any figure.
